Departamento de Ciencias do Mar, Universidade Federal de Sao Paulo, Santos, SP, BR.
Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceara, Fortaleza, CE, BR.
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e482s. doi: 10.6061/clinics/2018/e482s.
This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources.
这篇综述将讨论海洋天然分子的贡献,这些分子是最近才被发现具有药物前景的资源,可用于开发抗癌药物。在七种具有海洋来源的临床应用化合物中,有四种用于治疗癌症。这些药物的开发为应对这一领域最常见的挑战(如毒性和供应)提供了宝贵的知识和关键见解。在这种情况下,本文将讨论这些化合物的开发,通过提供阿糖胞苷、曲贝替定、艾日布林和本妥昔单抗维汀的成功实例,说明从海洋资源开发新药所涉及的步骤以及与开发新药相关的科学进步和技术创新潜力。